| Next 10 |
Ad
ABEO News and Press Abeona Therapeutics Inc.
-
Summary I sold out of Krystal Biotech stock after it hit my 65% profit price target. I am looking for another opportunity to enter. I just am not sure if I should be buying Krystal Biotech at current prices, given certain issues I discuss. Krystal Biotech ( KRYS ) has ...
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Alextype/Shutterstock.com We’re checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market! Short squeeze stocks are often subjec...
-
Abeona Therapeutics press release ( NASDAQ: ABEO ): Q3 GAAP EPS of -$1.48. Cash, cash equivalents, restricted cash and short-term investments totaled $23.5 million as of September 30, 2022. For further details see: Abeona Therapeutics GAAP EPS of -$1.48
-
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway into 3Q 2024 NEW YORK and CLEVELAND, Nov. 14, 2022 (GLOBE NEW...
-
Penny Stocks To Buy According To 5 Wall Street Analysts Are analysts the ultimate factor in deciding the best penny stocks to buy? In my opinion, they are not, and if you are using analyst ratings in your research, it’s sometimes best to take them with a grain of salt. But ar...
-
Summary Children suffering dystrophic epidermolysis bullosa (DEB), a serious genetic disease, are affectionately called butterfly children, depicting their fragile, recurrent blistering skin with chronic open wounds. Currently, there are three potential DEB treatments that have co...
-
Abeona Therapeutics ( NASDAQ: ABEO ) on Thursday said a phase 3 trial of its cell therapy EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) met its main goals. RDEB is a rare connective tissue disorder characterized by severe skin wounds tha...
-
Abeona Therapeutics ( NASDAQ: ABEO ) on Thursday announced $35M private placement financing . The company will sell ~7.1M shares, pre-funded warrants exercisable for 543.9K shares (in lieu of shares), and accompanying warrants to purchase 7.6M shares to a group of new and ...
-
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of its common stock, and, in lieu of shares of common stock, pre-funded warrants exercisable fo...
-
Co-primary endpoint measuring > 50% wound healing, other endpoints measuring > 75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greater magnitude of pain reduction benefit was o...
Stock Information
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
Get ABEO Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
